Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$55.74
pos +0.82
+1.50%
Today's Range: 55.18 - 55.89 | MRK Avg Daily Volume: 8,918,400
Last Update: 05/24/16 - 11:44 AM EDT
Volume: 1,903,762
YTD Performance: 3.98%
Open: $55.23
Previous Close: $54.92
52 Week Range: $45.69 - $61.70
Oustanding Shares: 2,768,025,348
Market Cap: 152,545,876,928
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 6 6
Moderate Buy 0 0 0 0
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.17 2.08 2.08
Latest Dividend: 0.46
Latest Dividend Yield: 3.34%
Dividend Ex-Date: 03/11/16
Price Earnings Ratio: 33.81
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
33.81 33.70 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.67% -7.51% 16.04%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.50 -0.20 -0.06
Net Income -62.60 -0.30 -0.11
EPS -61.60 -0.20 -0.08
Earnings for MRK:
EBITDA 13.92B
Revenue 39.50B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.91 $0.98 $3.73 $3.70
Number of Analysts 8 6 10 9
High Estimate $0.94 $1.00 $3.79 $3.88
Low Estimate $0.88 $0.96 $3.65 $3.34
Prior Year $0.86 $0.96 $3.59 $3.73
Growth Rate (Year over Year) 5.67% 2.08% 3.79% -0.73%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Update
May 24, 2016 | 7:27 AM EDT
MRK - Merck & Co Inc Annual Shareholders Meeting - 9AM
We offer 10 names each in the Opportunistic Value portfolio and the Income-Oriented portfolio.
It is hard to see much growth in the market overall, until earnings growth returns.
The expected legal deluge will be manageable thanks to JNJ's massive size and financial strength.
And Joe Papa can't stop the world. 
And it's hard to get excited about the second quarter, too.
Earnings season continued Thursday with oil prices helping lift the market. 
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
Bullish
Apr 07, 2016 | 7:45 AM EDT
MRK was initiated with a Buy rating, Societe Generale said. Valuation call, based on an $80 price target. 
Plus, the bears know where to lurk after a run.

Columnist Conversations

We are early in the WFC Investor Day meeting and while we don't expect any revelations which will drive the st...
Will we be saying "good-bye" to the head and shoulders formation on the S&P 500 chart and "hello" to a ris...
Market looks like it will open slightly higher based on futures. Just glancing through the headlines from the ...
Facebook continues to look vulnerable to me. I believe the stock put in a significant high on May 11 and...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.